BeiGene Ltd ADR
BGNE: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$562.28 | Hrpcmvs | — |
BeiGene Is a Commercial-Stage Biotech Firm and Conducts In-House Global Clinical Trials
Business Strategy and Outlook
BeiGene is an emerging Chinese biotechnology company with a global leading position in hematologic cancers thanks to its core drug Brukinsa. Since its approval in 2019, Brukinsa’s stronger efficacy and superior safety profile have allowed BeiGene to gain market share from existing drugs. In the next five years, we expect Brukinsa to continue contributing more than 50% of BeiGene’s total revenue.